Analyst Profile
Followed by 144 other investors
Serge Belanger
Needham
Wall Street Analyst
Ranked #1,262 out of 7,972 Analysts on TipRanks (#2,386 out of 21,851 overall experts)
Success Rate
137 out of 292 Profitable Transactions
Average Return
6.50%
Average return per transaction
Time Frame
Compare to
If you copied Serge Belanger's ratings since 2015 and opened each position for the duration of 1 Year:
46.92% of your transactions would have been profitable with an average return of 6.5%
Stock Rating Distribution
78.82% Buy
21.18% Hold
0.00% Sell
Distribution of Serge Belanger's ratings
Additional Information
Main Sector:Healthcare
Geo Coverage:
US Market
US MarketBest Rating
The most profitable rating made by Serge Belanger
Serge Belanger's Stock Coverage
Dyax Corp
Nov 05, 2015
Hold
Downgraded
―
―
0.00%
6
Altamira Therapeutics
Aug 19, 2016
Buy
Reiterated
$5.00
(1288.89% Upside)
―
0.00%
3
Pernix Therapeutics
Oct 03, 2016
Hold
Reiterated
―
―
0.00%
4
Evofem Biosciences
Jun 26, 2017
Hold
Reiterated
―
―
0.00%
2
Senomyx
Jul 24, 2017
Hold
Reiterated
―
―
0.00%
8
Corium
Oct 15, 2018
Hold
Downgraded
―
―
0.00%
7
Alder Biopharmaceuticals
Sep 16, 2019
Hold
Downgraded
―
―
0.00%
2
Dermira
Jan 24, 2020
Hold
Downgraded
―
―
0.00%
19
Amag Pharmaceuticals
Oct 01, 2020
Hold
Reiterated
―
―
0.00%
12
GW Pharma
Feb 03, 2021
Hold
Downgraded
―
+84.91%
14
List of latest recommendations made by Serge Belanger. Click to expand and see Serge Belanger's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More